Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Guardant Health, Inc. stock logo
GH
Guardant Health
$50.82
+2.6%
$45.51
$20.14
$53.42
$6.14B1.442.16 million shs2.29 million shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$48.96
+1.1%
$52.90
$13.47
$72.98
$10.84B2.0223.49 million shs30.53 million shs
Natera, Inc. stock logo
NTRA
Natera
$158.48
-0.1%
$160.52
$92.14
$183.00
$21.67B1.731.42 million shs1.06 million shs
Veracyte, Inc. stock logo
VCYT
Veracyte
$26.58
+0.9%
$27.90
$19.73
$47.32
$2.06B2.07913,654 shs739,796 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Guardant Health, Inc. stock logo
GH
Guardant Health
+2.58%+0.22%+5.74%+15.84%+84.33%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
+1.28%+2.28%-13.25%+66.57%+138.77%
Natera, Inc. stock logo
NTRA
Natera
-0.13%-1.39%-3.22%+4.28%+44.70%
Veracyte, Inc. stock logo
VCYT
Veracyte
+0.91%-2.71%-3.20%-18.52%+22.49%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Guardant Health, Inc. stock logo
GH
Guardant Health
3.8226 of 5 stars
2.51.00.04.43.82.50.6
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.162 of 5 stars
2.02.00.00.01.83.31.9
Natera, Inc. stock logo
NTRA
Natera
2.0882 of 5 stars
2.52.00.00.03.32.50.6
Veracyte, Inc. stock logo
VCYT
Veracyte
3.76 of 5 stars
3.41.00.04.33.50.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Guardant Health, Inc. stock logo
GH
Guardant Health
3.00
Buy$53.765.79% Upside
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
1.92
Reduce$39.58-19.15% Downside
Natera, Inc. stock logo
NTRA
Natera
3.00
Buy$184.6316.50% Upside
Veracyte, Inc. stock logo
VCYT
Veracyte
2.70
Moderate Buy$40.9053.88% Upside

Current Analyst Ratings Breakdown

Latest GH, VCYT, NTRA, and HIMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$45.00
6/23/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell ➝ Sell
6/23/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$30.00
6/23/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderperform ➝ Underperform
6/23/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
6/13/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$60.00 ➝ $65.00
6/11/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$40.00
6/4/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$61.00 ➝ $65.00
5/15/2025
Natera, Inc. stock logo
NTRA
Natera
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.00
5/9/2025
Natera, Inc. stock logo
NTRA
Natera
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$211.00 ➝ $218.00
5/9/2025
Natera, Inc. stock logo
NTRA
Natera
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Guardant Health, Inc. stock logo
GH
Guardant Health
$739.02M8.52N/AN/A($1.13) per share-44.97
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$1.48B7.42$0.36 per share137.49$2.16 per share22.67
Natera, Inc. stock logo
NTRA
Natera
$1.70B12.75N/AN/A$9.05 per share17.51
Veracyte, Inc. stock logo
VCYT
Veracyte
$445.76M4.67$1.05 per share25.40$15.17 per share1.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Guardant Health, Inc. stock logo
GH
Guardant Health
-$436.37M-$3.39N/AN/AN/A-53.82%N/A-26.77%8/6/2025 (Estimated)
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$126.04M$0.6970.9694.151.789.24%22.75%15.51%8/4/2025 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)
Veracyte, Inc. stock logo
VCYT
Veracyte
$24.14M$0.4164.8336.92N/A7.13%6.14%5.60%8/5/2025 (Estimated)

Latest GH, VCYT, NTRA, and HIMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Veracyte, Inc. stock logo
VCYT
Veracyte
$0.31N/AN/AN/A$120.90 millionN/A
8/4/2025Q2 2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.17N/AN/AN/A$550.06 millionN/A
5/8/2025Q1 2025
Natera, Inc. stock logo
NTRA
Natera
-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million
5/5/2025Q1 2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.12$0.20+$0.08$0.20$535.21 million$586.01 million
4/30/2025Q1 2025
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Guardant Health, Inc. stock logo
GH
Guardant Health
N/AN/AN/AN/AN/A
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
Veracyte, Inc. stock logo
VCYT
Veracyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Guardant Health, Inc. stock logo
GH
Guardant Health
N/A
4.11
3.76
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/A
1.59
1.32
Natera, Inc. stock logo
NTRA
Natera
N/A
3.87
3.74
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A
5.10
4.78

Institutional Ownership

CompanyInstitutional Ownership
Guardant Health, Inc. stock logo
GH
Guardant Health
92.60%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Natera, Inc. stock logo
NTRA
Natera
99.90%
Veracyte, Inc. stock logo
VCYT
Veracyte
N/A

Insider Ownership

CompanyInsider Ownership
Guardant Health, Inc. stock logo
GH
Guardant Health
6.10%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
17.71%
Natera, Inc. stock logo
NTRA
Natera
7.60%
Veracyte, Inc. stock logo
VCYT
Veracyte
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Guardant Health, Inc. stock logo
GH
Guardant Health
2,021123.89 million116.33 millionNot Optionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
1,637223.83 million184.19 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
4,434136.55 million126.17 millionOptionable
Veracyte, Inc. stock logo
VCYT
Veracyte
79078.32 million77.22 millionOptionable

Recent News About These Companies

Veracyte, Inc. (VCYT) - Yahoo Finance
Veracyte (NASDAQ:VCYT) Downgraded by Wall Street Zen to "Hold"

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Guardant Health stock logo

Guardant Health NASDAQ:GH

$50.82 +1.28 (+2.58%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$51.04 +0.22 (+0.43%)
As of 05:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$48.96 +0.54 (+1.12%)
Closing price 07/8/2025 03:59 PM Eastern
Extended Trading
$49.16 +0.20 (+0.42%)
As of 06:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Natera stock logo

Natera NASDAQ:NTRA

$158.48 -0.21 (-0.13%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$159.07 +0.59 (+0.37%)
As of 06:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Veracyte stock logo

Veracyte NASDAQ:VCYT

$26.58 +0.24 (+0.91%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$26.11 -0.47 (-1.76%)
As of 05:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.